Sharon Bio-Medicine
SHARONBIO · Pharma > Pharmaceuticals & Drugs · MD: Savita Satish Gowda · Listing date: Dec. 7, 2011

Stock Price vs Company Growth
5y
0.0%
10y
16.2%
all
14.9%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowSep07Mar11Sep14Mar18Sep21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

3.3 0%
N/A
3.3
Company Overview

Sales
395 Cr
Growth: -36.4%
Profit after Tax
-417 Cr
Growth: 51.7%
Micro Cap
34.8 Cr
P/S: 0.1x
Industry P/S: 2.5x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 395
Growth -36.4%
EBITDA -32.1%
P/S 0.1x
Dividend 0.0%
P/E -0.1x
Book Value ₹ -18.5
PEG Ratio 0.0x
ROE 999.0%
P/B N/A
Shareholding Pattern

Institutions
Created with Highcharts 8.2.2Mar16
Promoters
Created with Highcharts 8.2.2Mar16
Others
Pharmtak Ltd
2.61 %
Savita Surendra Pai
1.48 %
Santosh Ulkande
1.06 %
Virat Kumar Sharma
1.05 %
Bhagwandas K Sahu
1.04 %
Created with Highcharts 8.2.2Mar16
Increase    Decrease    No change
Company Profile Detailed

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs). The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.
Investors (26)
Followers (3)